Abstract
Epstein-Barr virus (EBV)-associated postallogeneic stem cell transplantation (SCT) lymphoproliferative disorder (PTLD) is often life threatening. The risk of EBV reactivation is highest in older patients, T cell-depleted SCT (in vivo or vitro), and in unrelated or mismatched SCT. Cumulative numbers of patients with EBV reactivation and PTLD are rising as more patients at high risk for EBV reactivation and PTLD are receiving allo-SCT. Novel but easily applicable strategies are needed to prevent EBV reactivation and PTLD to serve the needs of the increasingly enlarging population of high-risk SCT recipients across the globe.
Original language | English (US) |
---|---|
Pages (from-to) | 591-597 |
Number of pages | 7 |
Journal | Biology of Blood and Marrow Transplantation |
Volume | 17 |
Issue number | 5 |
DOIs | |
State | Published - May 2011 |
Keywords
- EBV reactivation
- Long-term survivors
- PTLD
- Rituximab
- Sirolimus
- Stem cell transplantation
ASJC Scopus subject areas
- Hematology
- Transplantation